Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4][9]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements [6][8]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA, citing the same cGMP deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 [8]. Group 3: Company Background - Unicycive Therapeutics, Inc. is publicly traded on NASDAQ under the ticker UNCY [4]. - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - It is also alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were overstated [2]. - The defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Unicycive Therapeutics, Inc. about a class action lawsuit due to alleged misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 29, 2024, to June 27, 2025, Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [3]. - It is claimed that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [3]. - As a result, the public statements made by the defendants were materially false and misleading throughout the relevant time [3]. Group 2: Class Action Details - Shareholders who purchased shares of UNCY during the specified class period are encouraged to register for the class action, with a deadline set for October 14, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The complaint against Unicycive alleges violations of federal securities laws due to false or misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its OLC NDA [2]. Group 1: Company Performance and Regulatory Issues - On June 10, 2025, Unicycive announced that the FDA identified deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a significant stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [3]. - On June 30, 2025, Unicycive disclosed that the FDA issued a Complete Response Letter for the OLC NDA, citing the same cGMP deficiencies, resulting in a further stock price decline of $2.03 per share, or 29.85%, closing at $4.77 [4]. Group 2: Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Whistleblower Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Unicycive's conduct, including whistleblowers and former employees, to come forward [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the specified class period [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 29, 2024, to June 27, 2025 [1]. - Allegations include that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by October 14, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged violations of the Securities Exchange Act of 1934, specifically regarding misleading statements made by the company and its officers during the class period from March 29, 2024, to June 7, 2025 [1][2]. Company Summary - The lawsuit claims that Unicycive and certain officers made false and misleading statements about the company's readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its lead drug candidate, oxylanthanum carbonate (OLC) [2][4]. - Key events impacting the company's stock include: - Submission of the New Drug Application (NDA) for OLC to the FDA in September 2024 [4]. - Disclosure of deficiencies in cGMP compliance at a third-party manufacturing subcontractor on June 10, 2025, leading to a 40.9% stock drop to $5.32 [4]. - Issuance of a Complete Response Letter (CRL) by the FDA rejecting the OLC NDA due to cGMP issues on June 30, 2025, resulting in a further 29.9% stock decline to $4.77 [4]. - Investors must seek lead plaintiff appointment by October 14, 2025 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged violations of the Securities Exchange Act of 1934, specifically regarding misleading statements about the company's FDA compliance and drug candidate prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Unicycive securities between March 29, 2024, and June 7, 2025 [1]. - Allegations include false statements regarding the company's readiness to meet FDA manufacturing compliance requirements [2]. - The suit also claims misleading information about the regulatory prospects of the lead drug candidate, oxylanthanum carbonate (OLC), for treating hyperphosphatemia in chronic kidney disease patients on dialysis [3]. Key Events - In September 2024, Unicycive submitted its New Drug Application (NDA) for OLC to the FDA [7]. - On June 10, 2025, the company disclosed that the FDA found deficiencies in cGMP compliance at a third-party manufacturing subcontractor, leading to a stock drop of 40.9% to $5.32 [7]. - On June 30, 2025, the FDA issued a Complete Response Letter (CRL) rejecting the OLC NDA due to the same cGMP issues, causing the stock to fall another 29.9% to $4.77 [7]. - Investors must seek lead plaintiff appointment by October 14, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025 [2]. - The Complaint alleges that Unicycive's management made materially false and misleading statements regarding the company's business operations and compliance policies [3]. - Specific allegations include overstated readiness to meet FDA manufacturing compliance requirements and exaggerated regulatory prospects for the OLC NDA [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Unicycive have until October 14, 2025, to request appointment as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering significant amounts for investors in securities fraud cases [6].

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025, inclusive (the "Class Period"). The Complaint alleges that Defendants made false and/or misleading st ...

ATLANTA, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC has filed a shareholder class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospe ...